07:02 AM EDT, 09/11/2024 (MT Newswires) -- Merck ( MRK ) said Wednesday that a phase 3 study of its experimental human papillomavirus vaccine, Gardasil 9, in Japanese males ages 16 to 26 years met primary and secondary goals.

The study demonstrated that the three-dose regimen of Gardasil 9 effectively reduced the incidence of anogenital infections caused by 9 types of HPV compared to a placebo.

The company said it plans to share the data with regulatory authorities in Japan and other countries to seek approval for use in males.

Price: 115.75, Change: +0.42, Percent Change: +0.36